Lazcluze (Lazertinib) is the latest medical breakthrough in the ongoing fight against non-small cell lung cancer (NSCLC). Officially approved by the Food and Drug Administration (FDA) on August 19, 2024, Lazcluze offers a novel therapeutic option for patients diagnosed with this aggressive and often difficult-to-treat form of cancer. Its advent marks a significant milestone in … Read more
Tecovirimat, also known by its brand name Tpoxx, represents a significant milestone in antiviral drug development, specifically targeting orthopoxvirus infections such as monkeypox. Tecovirimat was formulated to inhibit the activity of a protein essential for the virus’s ability to spread from an infected cell to others, effectively halting its proliferation within the host. This innovative … Read more
Can a new treatment change the lives of those living with vitiligo? The recent TRuE-V1 Study suggests it can. Vitiligo, a chronic skin condition that causes white patches due to pigment loss, has long had limited treatment options. A new clinical trial, the Topical Ruxolitinib Evaluation in VItiligo Study 1 (TRuE-V1), has revealed a game-changing … Read more
Donanemab got FDA approval on 2nd July 2024. The mechanism of action of Donanemab-azbt (Kisunla) is detailed here to understand how this new molecule can be a life-changer for people with Alzheimer’s disease. Kisunla (Donanemab) is a special type of medicine known as a monoclonal antibody. Monoclonal antibodies are lab-made molecules designed to fight diseases … Read more
On 24th April 2024, the FDA approves pivmecillinam under the brand name Pivya for treating uncomplicated UTIs in adult women. Uncomplicated urinary tract infections are caused by microorganisms like Staphylococcus saprophyticus, Proteus mirabilis, and Escherichia coli. The UTI infections caused by the above-mentioned bacteria are more common than others and affect almost 50% of women … Read more
WINREVAIR (Sotatercept-csrk) is a recombinant activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein. It blocks certain signals in the body. Specifically, it binds to and inhibits activin A and other TGF- β superfamily ligands. It corrects the imbalance between pro-proliferative (ActRIIA/Smad2/3-mediated) and anti-proliferative (BMPRII/Smad1/5/8 mediated) signaling mechanisms. By improving the bad inflammatory signals, it inhibits vascular … Read more
Daratumumab Mechanism of Action: Daratumumab is a human monoclonal antibody. It is indicated for the treatment of Multiple Myeloma in the following situations: In Combination With … Daratumumab Indications Lenalidomide + dexamethasone Newly diagnosed Multiple Myeloma patients ineligible for autologous stem cell transplant OR Patients with relapsed or refractory multiple myeloma who have received at … Read more
The FDA approved Berdazimer Gel 10.3% (Zelsuvmi) for Molluscum Contagiosum on 5th January 2024. Berdazimer Gel 10.3% (Zelsuvmi) is the second topical medicine approved so far for the treatment of Molluscum Contagiosum (MC). The first one, cantharidin, was approved in 2023. Curettage is more effective than Cantharidin. However, it has not been compared with Berdazimer … Read more
Why is Linzess dangerous? All medicines can be dangerous. Linzess is a prescription medicine and it has its Pros and Cons. It is indicated for the treatment of chronic constipation and individuals with constipation-dominant IBS. Because it relieves constipation, one of the side effects can be diarrhea. Diarrhea can occur with any of the medications … Read more
Yes! In clinical trials, hyperglycemia was reported in about 58% of the patients. TRUQAP (Capivasertib) is the most recently approved medicine for the treatment of breast cancer. It is recommended for women with the following [Ref]: Hormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative, Locally advanced or metastatic breast cancer with One or … Read more